Quarterly ResultMay 7, 2026, 01:38 PM
Teleflex Q1 Net Loss $(8.15)M; EPS $(0.18) Amid Divestitures & Restructuring
AI Summary
Teleflex reported a net loss of $(8.15) million, or $(0.18) diluted EPS, for the first quarter of 2026, a significant decline from a net income of $95.00 million in the prior year period. This loss was heavily influenced by a $(3.32) million loss from discontinued operations and increased restructuring and separation costs. Despite the overall loss, net revenues from continuing operations saw a substantial increase to $548.26 million, driven by growth across its Vascular, Interventional, and Surgical product categories, reflecting ongoing strategic divestitures and business integration efforts.
Key Highlights
- Teleflex reported a net loss of $(8.15) million for Q1 2026, compared to a net income of $95.00 million in Q1 2025.
- Diluted EPS was $(0.18) for Q1 2026, a decrease from $2.07 in Q1 2025.
- Net revenues from continuing operations increased to $548.26 million in Q1 2026 from $414.26 million in Q1 2025.
- Loss from discontinued operations was $(3.32) million in Q1 2026, compared to income of $42.67 million in Q1 2025.
- Restructuring, separation, and impairment charges for continuing operations were $16.85 million in Q1 2026, up from $1.42 million.
- Vascular segment net revenues grew to $236.81 million in Q1 2026 from $219.13 million in Q1 2025.
- Interventional segment net revenues surged to $204.66 million in Q1 2026 from $100.15 million in Q1 2025.
- Net cash provided by operating activities from continuing operations increased to $46.66 million in Q1 2026 from $27.72 million.
Price Impact
More from TFX